Item 8.01. Other Events.
On June 27, 2022, AmerisourceBergen Corporation (the "Company") and two other
national pharmaceutical distributors entered into an agreement with the State of
Oklahoma to resolve opioid-related claims. Pursuant to the agreement, the three
distributors will pay up to approximately $308 million, including attorneys'
fees and costs, to the State of Oklahoma and its participating subdivisions.
This amount is consistent with Oklahoma's allocation under the previously
announced comprehensive agreement to settle the vast majority of the opioid
lawsuits filed by state and local governmental entities. Upon effectiveness of
the Oklahoma settlement, the State of Oklahoma will dismiss its lawsuit against
the distributors with prejudice. The agreement is subject to certain
contingencies, including attaining the required rate of subdivision
participation by September 23, 2022.
While the Company strongly disputes the allegations made in the complaints filed
by the State of Oklahoma and its political subdivisions, it believes that
resolving all of such litigation will further its goal of achieving broad
resolution of governmental opioid claims while delivering meaningful relief to
communities across the United States that have been impacted by the opioid
epidemic.
Cautionary Statements Regarding Forward Looking Statements
The preceding descriptions of the resolution of certain opioids-related claims
against the Company constitute "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, that involve risks and uncertainties that could cause
actual results to differ materially from those in those statements. It is not
possible to identify all such risks and uncertainties. The reader should not
place undue reliance on forward-looking statements, which speak only as of the
date they are first made. Except to the extent required by law, the Company
undertakes no obligation to publicly update forward-looking statements.
Investors should read the important risk factors described in the Company's Form
10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange
Commission.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses